Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Pierre Amarenco; Larry B Goldstein; Alfred Callahan; Henrik Sillesen; Michael G Hennerici; Blair J O'Neill; Amy E Rudolph; Lisa Simunovic; Justin A Zivin; K M A Welch; Helle Klingenberg Iversen; SPARCL Investigators

doi:10.1016/j.atherosclerosis.2008.09.008

Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Pierre Amarenco, Larry B Goldstein, Alfred Callahan, Henrik Sillesen, Michael G Hennerici, Blair J O'Neill, Amy E Rudolph, Lisa Simunovic, Justin A Zivin, K M A Welch, Helle Klingenberg Iversen, SPARCL Investigators

Department of Neurology

94 Citations (Scopus)

Abstract

OBJECTIVE: To explore the relative contributions of baseline systolic blood pressure (SBP) and diastolic blood pressure (DBP) and lipoproteins on the risk of recurrent stroke or first major cardiovascular event (MCVE) and their potential impact on the benefit of statin treatment. METHODS AND RESULTS: The SPARCL trial randomized 4731 patients with recent stroke or transient ischemic attack (TIA) and no known coronary heart disease and LDL-C between 100 and 190 mg/dL to either atorvastatin 80 mg/d or placebo. Baseline assessment included SBP, DBP and measurements of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and triglyceride levels. After 4.9 years of follow-up, there were 575 primary end points (fatal and nonfatal stroke), including 491 ischemic strokes, and 740 MCVEs (stroke plus myocardial infarction and vascular death). Cox regression models analysis showed a trend (P>0.05 and P

Original language	English
Journal	Atherosclerosis
Volume	204
Issue number	2
Pages (from-to)	515-20
Number of pages	6
ISSN	0021-9150
DOIs	https://doi.org/10.1016/j.atherosclerosis.2008.09.008
Publication status	Published - 1 Jun 2009

Keywords

Aged
Blood Pressure
Cardiovascular Diseases
Cholesterol, HDL
Cholesterol, LDL
Female
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ischemic Attack, Transient
Male
Middle Aged
Proportional Hazards Models
Pyrroles
Recurrence
Risk Assessment
Risk Factors
Stroke
Time Factors
Treatment Outcome
Triglycerides

Access to Document

10.1016/j.atherosclerosis.2008.09.008

Cite this

Amarenco, P., Goldstein, L. B., Callahan, A., Sillesen, H., Hennerici, M. G., O'Neill, B. J., Rudolph, A. E., Simunovic, L., Zivin, J. A., Welch, K. M. A., Iversen, H. K., & SPARCL Investigators (2009). Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis, 204(2), 515-20. https://doi.org/10.1016/j.atherosclerosis.2008.09.008

Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. / Amarenco, Pierre; Goldstein, Larry B; Callahan, Alfred et al.
In: Atherosclerosis, Vol. 204, No. 2, 01.06.2009, p. 515-20.

Research output: Contribution to journal › Journal article › Research › peer-review

Amarenco, P, Goldstein, LB, Callahan, A, Sillesen, H, Hennerici, MG, O'Neill, BJ, Rudolph, AE, Simunovic, L, Zivin, JA, Welch, KMA, Iversen, HK & SPARCL Investigators 2009, 'Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial', Atherosclerosis, vol. 204, no. 2, pp. 515-20. https://doi.org/10.1016/j.atherosclerosis.2008.09.008

@article{3ba69696cbd14e7e8838004592fcc136,

title = "Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial",

abstract = "OBJECTIVE: To explore the relative contributions of baseline systolic blood pressure (SBP) and diastolic blood pressure (DBP) and lipoproteins on the risk of recurrent stroke or first major cardiovascular event (MCVE) and their potential impact on the benefit of statin treatment. METHODS AND RESULTS: The SPARCL trial randomized 4731 patients with recent stroke or transient ischemic attack (TIA) and no known coronary heart disease and LDL-C between 100 and 190 mg/dL to either atorvastatin 80 mg/d or placebo. Baseline assessment included SBP, DBP and measurements of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and triglyceride levels. After 4.9 years of follow-up, there were 575 primary end points (fatal and nonfatal stroke), including 491 ischemic strokes, and 740 MCVEs (stroke plus myocardial infarction and vascular death). Cox regression models analysis showed a trend (P>0.05 and P",

keywords = "Aged, Blood Pressure, Cardiovascular Diseases, Cholesterol, HDL, Cholesterol, LDL, Female, Heptanoic Acids, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Ischemic Attack, Transient, Male, Middle Aged, Proportional Hazards Models, Pyrroles, Recurrence, Risk Assessment, Risk Factors, Stroke, Time Factors, Treatment Outcome, Triglycerides",

author = "Pierre Amarenco and Goldstein, \{Larry B\} and Alfred Callahan and Henrik Sillesen and Hennerici, \{Michael G\} and O'Neill, \{Blair J\} and Rudolph, \{Amy E\} and Lisa Simunovic and Zivin, \{Justin A\} and Welch, \{K M A\} and Iversen, \{Helle Klingenberg\} and \{SPARCL Investigators\}",

note = "Helle Klingenberg Iversen er med i Study Group. Tilf{\o}jet manuelt i PURE",

year = "2009",

month = jun,

day = "1",

doi = "10.1016/j.atherosclerosis.2008.09.008",

language = "English",

volume = "204",

pages = "515--20",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

AU - Amarenco, Pierre

AU - Goldstein, Larry B

AU - Callahan, Alfred

AU - Sillesen, Henrik

AU - Hennerici, Michael G

AU - O'Neill, Blair J

AU - Rudolph, Amy E

AU - Simunovic, Lisa

AU - Zivin, Justin A

AU - Welch, K M A

AU - Iversen, Helle Klingenberg

AU - SPARCL Investigators

N1 - Helle Klingenberg Iversen er med i Study Group. Tilføjet manuelt i PURE

PY - 2009/6/1

Y1 - 2009/6/1

N2 - OBJECTIVE: To explore the relative contributions of baseline systolic blood pressure (SBP) and diastolic blood pressure (DBP) and lipoproteins on the risk of recurrent stroke or first major cardiovascular event (MCVE) and their potential impact on the benefit of statin treatment. METHODS AND RESULTS: The SPARCL trial randomized 4731 patients with recent stroke or transient ischemic attack (TIA) and no known coronary heart disease and LDL-C between 100 and 190 mg/dL to either atorvastatin 80 mg/d or placebo. Baseline assessment included SBP, DBP and measurements of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and triglyceride levels. After 4.9 years of follow-up, there were 575 primary end points (fatal and nonfatal stroke), including 491 ischemic strokes, and 740 MCVEs (stroke plus myocardial infarction and vascular death). Cox regression models analysis showed a trend (P>0.05 and P

AB - OBJECTIVE: To explore the relative contributions of baseline systolic blood pressure (SBP) and diastolic blood pressure (DBP) and lipoproteins on the risk of recurrent stroke or first major cardiovascular event (MCVE) and their potential impact on the benefit of statin treatment. METHODS AND RESULTS: The SPARCL trial randomized 4731 patients with recent stroke or transient ischemic attack (TIA) and no known coronary heart disease and LDL-C between 100 and 190 mg/dL to either atorvastatin 80 mg/d or placebo. Baseline assessment included SBP, DBP and measurements of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and triglyceride levels. After 4.9 years of follow-up, there were 575 primary end points (fatal and nonfatal stroke), including 491 ischemic strokes, and 740 MCVEs (stroke plus myocardial infarction and vascular death). Cox regression models analysis showed a trend (P>0.05 and P

KW - Aged

KW - Blood Pressure

KW - Cardiovascular Diseases

KW - Cholesterol, HDL

KW - Cholesterol, LDL

KW - Female

KW - Heptanoic Acids

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Ischemic Attack, Transient

KW - Male

KW - Middle Aged

KW - Proportional Hazards Models

KW - Pyrroles

KW - Recurrence

KW - Risk Assessment

KW - Risk Factors

KW - Stroke

KW - Time Factors

KW - Treatment Outcome

KW - Triglycerides

UR - https://www.scopus.com/pages/publications/67349087272

U2 - 10.1016/j.atherosclerosis.2008.09.008

DO - 10.1016/j.atherosclerosis.2008.09.008

M3 - Journal article

C2 - 18962621

SN - 0021-9150

VL - 204

SP - 515

EP - 520

JO - Atherosclerosis

JF - Atherosclerosis

IS - 2

ER -

Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this